0.690
-0.30 (-30.48%)
| Penutupan Terdahulu | 0.993 |
| Jumlah Dagangan | 69,697 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.830 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.70% |
| Nisbah Semasa (MRQ) | 11.85 |
| Aliran Tunai Operasi (OCF TTM) | -29.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -14.01 M |
| Pulangan Atas Aset (ROA TTM) | -28.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -47.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Skye Bioscience, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | -0.3 |
| AI Technical info | NA |
| Osilator Teknikal info | -0.5 |
| Purata Bergerak Teknikal info | 0.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -17.9% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 2.6 |
| Skor Akhir | -0.13 |
|
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.44% |
| % Dimiliki oleh Institusi | 80.76% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Platinum Investment Management Ltd | 30 Jun 2026 | 29,137 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |